Tags

Type your tag names separated by a space and hit enter

Current pharmacological treatments for SARS-COV-2: A narrative review.
Eur J Pharmacol. 2020 Sep 05; 882:173328.EJ

Abstract

The novel coronavirus, later identified as SARS-CoV-2, originating from Wuhan in China in November 2019, quickly spread around the world becoming a pandemic. Despite the knowledge of previous coronaviruses, such as those responsible for the SARS and MERS-CoV epidemic, there is no drug or prophylaxis treatment to this day. The rapid succession of scientific findings on SARS-CoV-2 provides a significant number of potential drug targets. Nevertheless, at the same time, the high quantity of clinical data, generated by a large number of rapidly infected people, require accurate tests regarding effective medical treatments. Several in vitro and in vivo studies were rapidly initiated after the outbreak of the pandemic COVID-19. Initial clinical studies revealed the promising potential of remdesivir that demonstrated a powerful and specific in vitro antiviral activity for COVID-19. Promising effects appear to be attributable to hydroxychloroquine. Remdesivir and hydroxychloroquine are being tested in ongoing randomized trials. In contrast, oseltamivir was not effective and corticosteroids are not currently recommended. However, few data from ongoing clinical trials are identifying low molecular weight heparins, innate immune system stimulating agents, and inflammatory modulating agents as potential effective agents. The authors assume that the current pandemic will determine the need for a systematic approach based on big data analysis for identifying effective drugs to defeat SARS-Cov-2. This work is aimed to be a general reference point and to provide an overview as comprehensive as possible regarding the main clinical trials in progress at the moment.

Authors+Show Affiliations

School of Pharmacy and Health Products, Telemedicine and Telepharmacy Center, University of Camerino, Via Madonna Delle Carceri 9, Camerino, MC, 62032, Italy.School of Pharmacy and Health Products, Telemedicine and Telepharmacy Center, University of Camerino, Via Madonna Delle Carceri 9, Camerino, MC, 62032, Italy. Electronic address: graziano.pallotta@unicam.it.School of Pharmacy and Health Products, Telemedicine and Telepharmacy Center, University of Camerino, Via Madonna Delle Carceri 9, Camerino, MC, 62032, Italy; Research Department of International Radio Medical Center (CIRM), Via Dell'Architettura 41, Rome, 00144, Italy.School of Pharmacy and Health Products, Telemedicine and Telepharmacy Center, University of Camerino, Via Madonna Delle Carceri 9, Camerino, MC, 62032, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32603692

Citation

Nittari, Giulio, et al. "Current Pharmacological Treatments for SARS-COV-2: a Narrative Review." European Journal of Pharmacology, vol. 882, 2020, p. 173328.
Nittari G, Pallotta G, Amenta F, et al. Current pharmacological treatments for SARS-COV-2: A narrative review. Eur J Pharmacol. 2020;882:173328.
Nittari, G., Pallotta, G., Amenta, F., & Tayebati, S. K. (2020). Current pharmacological treatments for SARS-COV-2: A narrative review. European Journal of Pharmacology, 882, 173328. https://doi.org/10.1016/j.ejphar.2020.173328
Nittari G, et al. Current Pharmacological Treatments for SARS-COV-2: a Narrative Review. Eur J Pharmacol. 2020 Sep 5;882:173328. PubMed PMID: 32603692.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current pharmacological treatments for SARS-COV-2: A narrative review. AU - Nittari,Giulio, AU - Pallotta,Graziano, AU - Amenta,Francesco, AU - Tayebati,Seyed Khosrow, Y1 - 2020/06/27/ PY - 2020/05/13/received PY - 2020/06/26/revised PY - 2020/06/26/accepted PY - 2020/7/1/pubmed PY - 2020/8/8/medline PY - 2020/7/1/entrez KW - COVID-19 KW - Clinical trials KW - Coronavirus KW - Pharmacological treatments KW - SARS-CoV-2 KW - Therapies SP - 173328 EP - 173328 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 882 N2 - The novel coronavirus, later identified as SARS-CoV-2, originating from Wuhan in China in November 2019, quickly spread around the world becoming a pandemic. Despite the knowledge of previous coronaviruses, such as those responsible for the SARS and MERS-CoV epidemic, there is no drug or prophylaxis treatment to this day. The rapid succession of scientific findings on SARS-CoV-2 provides a significant number of potential drug targets. Nevertheless, at the same time, the high quantity of clinical data, generated by a large number of rapidly infected people, require accurate tests regarding effective medical treatments. Several in vitro and in vivo studies were rapidly initiated after the outbreak of the pandemic COVID-19. Initial clinical studies revealed the promising potential of remdesivir that demonstrated a powerful and specific in vitro antiviral activity for COVID-19. Promising effects appear to be attributable to hydroxychloroquine. Remdesivir and hydroxychloroquine are being tested in ongoing randomized trials. In contrast, oseltamivir was not effective and corticosteroids are not currently recommended. However, few data from ongoing clinical trials are identifying low molecular weight heparins, innate immune system stimulating agents, and inflammatory modulating agents as potential effective agents. The authors assume that the current pandemic will determine the need for a systematic approach based on big data analysis for identifying effective drugs to defeat SARS-Cov-2. This work is aimed to be a general reference point and to provide an overview as comprehensive as possible regarding the main clinical trials in progress at the moment. SN - 1879-0712 UR - https://www.unboundmedicine.com/medline/citation/32603692/Current_pharmacological_treatments_for_SARS_COV_2:_A_narrative_review_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(20)30420-9 DB - PRIME DP - Unbound Medicine ER -